Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 19, 2025Phytotherapy ResearchOpen Access

Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review

View Full Paper
Ask AI
Bookmark
Share

Authors

EWElizabeth M. WilliamsonTBThomas Brendler

Discussion

Loading...

Member takes

Overview

Preclinical evidence reviews the safety of ashwagandha, highlighting liver toxicity reports and antitumorigenic effects.

Key Points

  • Ashwagandha has been widely recognized as a safe herb, though liver toxicity cases have emerged unexpectedly.
  • While most studies support its safety, instances of reversible cholestasis and severe jaundice have been documented without clear preclinical warnings.
  • Withaferin-A, a key constituent, displays promising antitumorigenic properties in liver cancer models, indicating therapeutic potential.
  • The herb has not evidenced genotoxicity or mutagenicity, contradicting some folkloric claims of harm related to reproduction.

Cite This Study

Williamson et al. (2025) studied this question.

synapsesocial.com/papers/68d466a831b076d99fa64ff7https://doi.org/10.1002/ptr.70090
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety assessment of Withania somnifera extract standardized for Withaferin A: Acute and sub-acute toxicity study2016 · 107 citations
  2. 2ACUTE AND SUB CHRONIC TOXICITY STUDIES OF PURIFIED WITHANIA SOMNIFERA EXTRACT IN RATS2018 · 20 citations
  3. 3Withaferin A attenuates ovarian cancer-induced cardiac cachexia2020 · 24 citations
  4. 4Withania somnifera (L.) Dunal whole-plant extract demonstrates acceptable non-clinical safety in rat 28-day subacute toxicity evaluation under GLP-compliance2022 · 19 citations
  5. 5Changes in Thyroid Hormone Concentrations after Administration of Ashwagandha Root Extract to Adult Male Mice1998 · 100 citations